Published On: Thu, Feb 19th, 2015

NYU, Technion Forge Groundbreaking Partnership in Cancer Research

NYU Langone is a world-renowned leader in the investigation and treatment of cancer. The Technion is one of Israel's leading academic and research centers and a top-ranked science and technology global research university.

NYU Langone Medical Center

NYU Langone Medical Center and the Technion-Israel Institute of Technology — formally received a $9 million gift from philanthropists Laura and Isaac Perlmutter that will fund two major, joint research endeavors with potentially far-reaching impact in advancing cancer research. The joint program is positioned to attract additional, world-class support from institutions and individuals who are dedicated to eradicating cancer through focused and efficient research.

The first $3 million of the grant will finance six cancer-focused research projects that will be conducted by teams spearheaded by co-investigators from both NYU Langone and the Technion. The remaining $6 million will be used to establish a state-of-the-art research facility on Technion’s campus in Israel that will support these and other research projects– and which will have a principal focus on the emerging field of cancer metabolomics.

NYU Langone is a world-renowned leader in the investigation and treatment of cancer. The Technion is one of Israel’s leading academic and research centers and a top-ranked science and technology global research university.

“NYU Langone and the Technion have a shared, longstanding commitment to advancing cancer research, ” said Dafna Bar-Sagi, PhD, senior vice president and vice dean for science at NYU Langone, chief science officer at NYU School of Medicine, and a principal architect of the NYU Langone-Technion partnership. “We are now at a great moment in our institutions’ illustrious histories, a point from which we can jointly leverage the talent and creativity of our researchers toward accelerating breakthroughs. The foresight and the generosity of the Perlmutters, particularly at this time of financial challenge in funding for basic research, will have tremendous impact.”

“Bringing together the unique expertise of researchers from both NYU and the Technion will hopefully enable us to overcome some of the most difficult challenges in treating cancer patients, ” said Technion Distinguished Professor Aaron Ciechanover, MD, D.Sc., the 2004 Nobel Prize Laureate in Chemistry, and Distinguished Research Professor and head of the David and Janet Polak Cancer and Vascular Biology Research Center at the Technion Faculty of Medicine.
Internationally Renowned Researchers to Lead the Charge

The latest gift from the Perlmutters coincides with two new appointments at NYU Langone and the Technion that will be integral to the partnership. Renowned cancer biologist Benjamin G. Neel, MD, PhD, an expert in the field of cell signal transduction, recently joined the NYU Langone faculty as director of the Perlmutter Cancer Center, and Eyal Gottlieb, PhD, a world leader in cancer metabolism, has been recruited to lead the new research facility at the Technion funded by the Perlmutter gift – and spearhead joint efforts in cancer metabolomics.

Read more about: , , , , , ,

Wordpress site Developed by Fixing WordPress Problems